According to a recent study published in Frontiers in Nutrition , ketogenic metabolic therapy (KMT ) works synergistically with IDH1 mutation in glioblastoma (GBM) patients by targeting the metabolic pathways that are essential for the growth of glioblastoma. A British man diagnosed with glioblastoma in 2014 refused to undergo the standard of care to treat cancer, including resection, radiation, and chemotherapy, which result in significant toxicity. Instead, he adopted a low-carbohydrate, high-fat ketogenic diet to maintain low Glucose Ketone Index (GKI) values, indicative of therapeutic ketosis, to manage his cancer.
Key findings of the study: The median survival time of 11-15 months after diagnosis for glioblastoma patients has not improved even after introducing new immunotherapy. In this case, the patient's tumor continued to grow gradually over three years without expected…
